Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To. The firm mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
根据最新的财务报表(Form-10K),Astellas Pharma Inc. 的总资产为 $0,净손실为 $0
ALPMY 的关键财务比率是什么?
Astellas Pharma Inc. 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
Astellas Pharma Inc. 的收入按细分市场或地理位置如何划分?
Astellas Pharma Inc. 주요 수익원은 Pharmaceutical이며, 최신 수익 발표에서 수익은 1,912,323,000,000입니다. 지역별로는 United States이 Astellas Pharma Inc.의 주요 시장이며, 수익은 866,378,000,000입니다.